$RNN Recent News Rexahn prices offering at 30% discount

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$RNN Recent News

Rexahn prices offering at 30% discount 10:58 a.m. Nov. 29, 2012 - MarketWatch.com
AEterna falls; Inspire, Rexahn rally 2:15 p.m. April 16, 2010 - Val Brickates Kennedy
Javelin rockets, Myriad gains on scrapped merger 12:20 p.m. April 12, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 3:26 p.m. April 7, 2010 - MarketWatch
Rexahn, Avanir gain; Sequenom falls 12:32 p.m. April 7, 2010 - Val Brickates Kennedy
Letter up 230% last year without trading 3:00 a.m. Jan. 11, 2010 - Peter Brimelow

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013 7:00 a.m. Jan. 21, 2014 - TheStreet.com
Rexahn Pharmaceutical Shares Are Still A Buy Despite Recent Volatility 3:38 p.m. Jan. 15, 2014 - Seeking Alpha
Rexahn Pharma slides after announcing offering 9:11 a.m. Jan. 15, 2014 - Seeking Alpha
3 Biotechs Getting Plenty Of Attention From Investors 8:26 a.m. Jan. 15, 2014 - Seeking Alpha
Morning Market Losers 9:02 a.m. Jan. 14, 2014 - benzinga.com
Morning Market Movers 8:55 a.m. Jan. 13, 2014 - benzinga.com
Why Rexahn Pharmaceuticals (RNN) Is Up Today 10:35 a.m. Jan. 10, 2014 - TheStreet.com
Rexahn up 15% after Buy rating 1:25 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn's Replacement For Eli Lilly's Gemzar Enters New Clinical Trial 12:20 p.m. Jan. 9, 2014 - Seeking Alpha
Rexahn: A Turn Around Story For 2014 12:49 p.m. Dec. 22, 2013 - Seeking Alpha
Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment 1:47 p.m. Nov. 25, 2013 - Seeking Alpha
Rexahn's Recent Clinical Data Points To A New And Better Chemotherapy Pill 7:57 p.m. Oct. 6, 2013 - Seeking Alpha
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 6:02 a.m. Sept. 30, 2013 - benzinga.com
Rexahn Regains Rights To Novel Cancer Drug As Teva Continues Its Pipeline Stumble 4:06 p.m. Sept. 5, 2013 - Seeking Alpha
Teva-Rexahn Deal Terminated - Analyst Blog 10:40 a.m. Aug. 30, 2013 - Zacks.com
10-Q: REXAHN PHARMACEUTICALS, INC. 3:15 p.m. Aug. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors 6:01 a.m. Aug. 7, 2013 - benzinga.com
Rexahn's CEO Uses A Business-Driven Cancer Model For Shareholder Value 5:34 p.m. Aug. 5, 2013 - Seeking Alpha
Rexahn Redesigns Cancer Superdrug Taxotere 12:58 p.m. July 18, 2013 - Seeking Alpha
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 6:05 a.m. July 17, 2013 - benzinga.com


Opening Buzzers: Chelsea Therapeutics International, Tesla Motors Inc, NQ Mobile Inc, Rexahn Pharmaceuticals 11:02 a.m. Jan. 15, 2014 - ACCESSWIRE
Rexahn Announces $20 Million Registered Direct Offering 8:59 a.m. Jan. 15, 2014 - BusinessWire - BZX
Rexahn Initiates Phase IIa Clinical Trial of Archexin® in Patients with Metastatic Renal Cell Carcinoma 9:00 a.m. Jan. 14, 2014 - BusinessWire - BZX
Rexahn Initiates Phase Ib Clinical Trial of RX-3117 for Treatment of Solid Tumors 8:00 a.m. Jan. 8, 2014 - BusinessWire
Rexahn Pharmaceuticals to Present at the Biotech Showcase 2014 8:00 a.m. Jan. 7, 2014 - BusinessWire
Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for Supinoxin (TM) (RX-5902) 8:17 a.m. Dec. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals to Participate in Brean Capital 2013 Life Sciences Summit 8:00 a.m. Nov. 19, 2013 - BusinessWire
Rexahn Pharmaceuticals Reports Third Quarter Financial Results and Pipeline Update 8:00 a.m. Nov. 14, 2013 - BusinessWire
Rexahn Announces $5.3 Million At Market Registered Direct Offering 8:00 a.m. Oct. 11, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University 7:00 a.m. Oct. 10, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 7:00 a.m. Sept. 30, 2013 - BusinessWire
Rexahn Awarded Patent in Europe for Cancer Drug Archexin(R) 7:00 a.m. Sept. 12, 2013 - BusinessWire
Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 7:00 a.m. Sept. 5, 2013 - BusinessWire
Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update 7:00 a.m. Sept. 4, 2013 - BusinessWire
Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117 8:00 a.m. Aug. 28, 2013 - BusinessWire
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of Supinoxin(TM) (RX-5902) a Candidate for Treating Solid Cancer Tumors 7:00 a.m. Aug. 7, 2013 - BusinessWire
University Of Maryland, Baltimore's Licensing Deals Fuel Local Life Sciences Community 7:30 a.m. Aug. 6, 2013 - PR Newswire
Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering 8:00 a.m. July 24, 2013 - BusinessWire
Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform 7:00 a.m. July 17, 2013 - BusinessWire
Rexahn Pharmaceuticals Announce IND Submission for RX-3117 7:00 a.m. July 15, 2013 - BusinessWire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 62

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 271

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 135

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 255

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 139

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 190

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kearney's 2025 Global Cities Report Insights

Updated Category News Views 654

Global Cities Adapt to New Challenges and Emergence Global cities hold steady at the top as new hubs surge forward Top cities reaffirm their dominance in the Global Cities Index, showcasing remarkable resilience amidst global changes and uncertainties. The Global Cities Outlook indicates a noticeable shift as traditional leaders face turbulence, while emerging Gulf and...

Continue Reading
Vacca Family Law Group Enhances Support for Peaceful Divorce

Updated Category News Views 255

Empowering Families Through Non-Adversarial Divorce Solutions Families navigating the challenging process of separation now have renewed access to considerate and non-confrontational divorce options. Vacca Family Law Group has recently welcomed Attorney and Mediator Wendy Reimer, who brings nearly two decades of experience in family law and a strong background in...

Continue Reading
Ingredion Delivers Impressive Q3 Results, Upgrades Outlook

Updated Category News Views 55

Ingredion's Strong Performance in the Third Quarter Ingredion Incorporated (NYSE: INGR) has reported remarkable results for the third quarter of 2024, showcasing a noteworthy surge in both operating income and earnings per share (EPS). The global leader in ingredient solutions for the food and beverage industry achieved a stunning 26% increase in reported operating income...

Continue Reading
Insight into Learning Technologies Group Plc's Disclosure Mechanism

Updated Category News Views 193

Understanding the Public Opening Position Disclosure Process In the complex world of financial securities, understanding the disclosure requirements can feel daunting. However, the process outlined by the Takeover Code, particularly Rule 8.3, provides a structured approach for individuals and entities holding significant interests in relevant securities. This rule is...

Continue Reading
Avidity Biosciences Set to Inspire with Latest Presentations

Updated Category News Views 191

Avidity Biosciences' Key Presentations at the MDA Conference Avidity Biosciences, Inc. (Nasdaq: RNA), a pioneer in RNA therapeutics, is poised to make a significant impact at the upcoming Clinical and Scientific Conference organized by the Muscular Dystrophy Association (MDA). The event will showcase the latest advancements in the field and highlight groundbreaking...

Continue Reading